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Abstract  
BACKGROUND&AIMS: Use of dabigatran, an inhibitor of thrombin, increases risk of 
gastrointestinal bleeding (GIB). However, it is not clear whether gastroprotective agents (GPAs) 
prevent GIB in dabigatran users. We investigated the risk of GIB and the role of GPAs 
(including proton-pump inhibitors and histamine type-2 receptor antagonists) in patients using 
dabigatran.  
METHODS: We performed a retrospective cohort study using a population-wide database 
managed by the Hong Kong Hospital Authority. Patients newly prescribed dabigatran from 2010 
through 2013 were included in the analysis. Poisson regression was used to assess the risk of 
GIB in dabigatran users by incidence rate ratio (IRR), adjusted for patient characteristics, 
comorbidities, and concurrent medications. 
RESULTS: Among the 5041 patients newly prescribed dabigatran, 124 (2.5%) developed GIB 
during follow-up (4.2/100 patient-years). The risk of GIB in this population increased among 
patients 75 y old or older (IRR, 2.47; 95% confidence interval [CI], 1.66–3.68), patients with a 
history of peptic ulcers or GIB (IRR, 2.31; 95% CI, 1.54–3.46), and patients who used aspirin 
(IRR, 1.52; 95% CI, 1.03–2.24). Concomitant use of GPAs was associated with a reduced risk of 
GIB (IRR, 0.52; 95% CI, 0.35–0.77). Subcategory analysis showed that use of proton-pump 
inhibitors (IRR, 0.53; 95% CI, 0.31–0.91) or histamine type-2 receptor antagonists (IRR, 0.61; 
95% CI, 0.40–0.94) were associated with lower risk of GIB. Further analysis revealed that the 
risk reduction by GPAs was significant for only upper GIB (IRR, 0.29; 95% CI, 0.15–0.54) and 
only for patients with prior history of peptic ulcers or GIB (IRR, 0.14; 95% CI, 0.06–0.30). 
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CONCLUSIONS: In the Hong Kong population, use of GPAs and was associated with a 
reduced risk of GIB in patients taking dabigatran. The association was stronger for upper GIB 
than lower GIB, and in patients with prior history of peptic ulcers or GIB. 
KEYWORDS: anticoagulant; drug side effect; PPI; H2RA  
Word count: 312  
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Introduction 
Dabigatran, an oral direct thrombin inhibitor1, is the first novel oral anticoagulants (NOACs) 
approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial 
fibrillation (AF). Unlike traditional oral anticoagulant warfarin, dabigatran has a predictable 
pharmacokinetic profile and does not require frequent blood monitoring. In the Randomized 
Evaluation of the Long-Term Anticoagulation Therapy (RE-LY) trial, dabigatran 150mg twice 
daily was superior to warfarin in the prevention of stroke and systemic embolism in AF patients 
and non-inferior to warfarin at 110mg twice daily.2  
Despite its comparable efficacy and relative convenience, several randomized controlled trials 
and reports have demonstrated that the risk of gastrointestinal bleeding (GIB) is higher with the 
use of dabigatran than traditional therapies across different indications.2-5 A recent systematic 
review on previous clinical trials demonstrated that the pooled odds ratio (OR) of GIB associated 
with dabigatran use was 1.6 when compared to traditional therapies including warfarin.6 
Recently, the U.S. Food and Drug Administration (FDA) released a safety announcement that 
dabigatran is associated with a higher rate of gastrointestinal bleeding compared with warfarin in 
patients with non-valvular AF, based on their latest analysis of the Mini-Sentinel database.7 
However, the actual bleeding risk of dabigatran use for various indications in daily clinical 
practice outside restrictive clinical trial setting is less well described.  
Although current guidelines recommend that proton pump inhibitors (PPIs) should be considered 
in patients at high risk of GIB receiving antithrombotic therapy,6,8-10 the role of gastroprotective 
agents including PPIs and histamine type-2 receptor antagonists (H2RAs) in the prevention of 
GIB associated with dabigatran remains undefined.  
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This study determined the risk of GIB in patients newly prescribed with dabigatran in a large 
population based retrospective cohort study from Hong Kong. We also identified the risk factors 
and the effects of gastroprotective agents in dabigatran associated GIB in this cohort.   
Method 
Data source 
This study used the electronic medical records of the Clinical Data Analysis and Reporting 
System (CDARS) of the Hong Kong Hospital Authority (HA), which is the sole public-funded 
healthcare provider of Hong Kong. The HA is currently serving a population of over seven 
million, managing 42 hospitals, 47 Specialist Out-patient Clinics, and 73 General Out-patient 
Clinics organized into seven hospital clusters according to geographical locations.11 The HA uses 
the Clinical Management System (CMS), a computerized clinical management system, to record 
all key clinical information such as treatment, diagnoses, prescriptions, laboratory results and 
procedures information; and to write consultation and discharge summaries.12 It also allows 
clinicians and health care specialists to order and review care in their daily practice.13 Electronic 
patient records in the HA, including demographics, date of consultation, date of hospital 
admission and discharge, diagnoses, procedures, drug prescriptions and laboratory tests were  
transferred from CMS to CDARS for audit and research propose.13 CDARS has been used for 
conducting high quality population-based studies.13-17 A local study demonstrated a high 
accuracy of coding in CDARS with a positive predictive value of 90%.18 Nonetheless, we 
conducted further validation on a sample of patients in this cohort to ensure the validity of our 
dataset. 
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All patient records in CDARS are anonymized to protect patient confidentially. A unique 
reference number is allocated for each individual patient to facilitate data retrieval and further 
analysis. The study protocol was approved by the Institutional Review Board of the University of 
Hong Kong/Hospital Authority Hong Kong West Cluster (reference number: UW 13-468). 
Informed consent from patients was not required since the data used in this study were 
anonymized. 
Study design 
This is a retrospective cohort study. We identified all patients who were newly prescribed with 
dabigatran between 1st Jan 2010 and 31st Dec 2013 from the CDARS. The index date was 
defined as the date of the first dabigatran prescription. The follow-up of each patient was 
commenced from the index date until the development of GIB, death, the prescription of an 
alternative anticoagulant (warfarin, rivaroxaban or apixaban), the end of the study period (31st 
Dec 2013) or 30 days after discontinuation (defined as >30 days of interval between prescription 
refills) of dabigatran, whichever came first. Another 30-day follow-up was added after the final 
prescription of dabigatran to account for non-compliance and capture any GIB that may have led 
to treatment discontinuation. Patients who had received dabigatran in the 12 months prior to the 
index date and patients who were prescribed other anticoagulants on the index date were 
excluded. Patient’s coexisting medical illnesses prior to the index date and drugs concurrently 
prescribed in the follow-up period were retrieved from the CDARS (Figure 1).  
Outcome and covariates 
The primary outcome was the development of GIB after the prescription of dabigatran. Patients 
who developed GIB were identified in CDARS with the physician assigned International 
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Classification of Diseases codes (Ninth Revision, Clinical Modification (ICD-9); Supplementary 
Table 1). We included possible diagnoses of GIB including peptic ulcer hemorrhage (531.0, 
531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 533.6, 534.0, 534.2, 534.4, 
534.6), bleeding gastritis and/or duodenitis (535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 
535.61, 535.71), intestinal hemorrhage (562.02, 562.03, 562.12, 562.13, 569.3, 569.85, 569.86) 
and gastrointestinal hemorrhage (578). Upper GIB and non-upper GIB were classified by the 
diagnostic codes and free text information in CDARS (Supplementary Table 1). 
The use of the following medications during follow-up was included as covariates in terms of 
dichotomous variables (present/absent) in the analysis (Figure 1): use of aspirin, clopidogrel, 
nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), histamine type-2 
receptor antagonists (H2RAs), and selective serotonin reuptake inhibitors (SSRIs).19-23 Baseline 
medical conditions including prior ischemic stroke/transient ischemic attack/systemic embolism, 
renal disease, and prior history of peptic ulcer/GIB were also counted as dichotomous covariates 
in the analysis.20-22 For each patient, all diagnosis records dated prior to the individual index date 
were retrieved using ICD-9 codes (Supplementary Table 1) from CDARS for the identification 
of the baseline medical conditions.  
Data validation  
To validate the coding accuracy, we extracted the original medical records in the CMS of a 
sample of patients (Supplementary Figure 1) from the Hong Kong West (HKW) cluster, which is 
one of the seven hospital clusters (a group of hospitals under the same management structure in a 
region of Hong Kong) of the HA. The HKW cluster comprises seven hospitals, one specialist 
rehabilitation center, and six general out-patient clinics in the Central & Western District and the 
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Southern District of Hong Kong.24 The HKW cluster region has a population of over half a 
million, representing about 8% of the Hong Kong population.24 The age and gender distribution 
in the HKW cluster region are similar to that of the overall population in Hong Kong.25 The 
HKW cluster also provides services to patients residing outside its cluster region through cross-
cluster referrals. In particular,  it hosts one of the two university teaching hospitals in Hong Kong, 
the Queen Mary Hospital, which is a tertiary referral center for all complex cases.24 
A gastroenterologist (WKL) manually reviewed the patient records to validate the diagnosis of 
GIB (Supplementary Table 1). The identifications of two important patient characteristics were 
also validated in our cohort from CDARS – prior history of peptic ulcer/GIB and history of AF 
(as indication). The cases of GIB and peptic ulcers were confirmed by endoscopy findings, 
pathology reports, surgery, radiology, autopsy, clinical symptoms (e.g. hematemesis, melena) or 
documentation of the diseases in medical chart. The diagnosis of AF was ascertained by 
electrocardiogram, Holter monitor findings, or any documentation of the disease history or 
indication for dabigatran. Patients on dabigatran with no GIB, no prior history of peptic 
ulcer/GIB, or received dabigatran for indications other than AF were randomly selected to serve 
as negative controls. The corresponding positive predictive value (PPV) and negative predictive 
value (NPV) were calculated. 
Statistical analysis 
Continuous variables were reported as mean ± standard deviation whereas categorical data were 
expressed as frequencies (percentages), respectively. Risk time was measured from the index 
date when dabigatran was prescribed until the development of GIB. Conditional Poisson 
regression was used to determine the risk of GIB, in terms of incidence rate ratio (IRR) with 95% 
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confidence intervals (CI), among patients who were taking dabigatran after controlling for 
baseline medical conditions and use of concurrent medications. Patients who had a prescription 
of either H2RA and/or PPI during follow-up (regardless of the duration of medication) were 
defined as users of gastroprotective agents. Subgroup analyses were conducted by classifying 
patients into three groups according to their drug exposures: 1) H2RA only; 2) PPI only; and 3) 
both H2RA and PPI (either prescribed simultaneously or sequentially).  
The times to GIB for users and non-users of gastroprotective agents were illustrated by Kaplan-
Meier curves and compared using the Cox proportional hazards regression model in hazard ratios 
(HR), with adjustment for baseline characteristics and use of concurrent medications as 
previously mentioned.  
We conducted further subgroup analysis to examine the effect of gastroprotective agents in new 
OAC “starters” and “switchers” from other OACs, since they may have different bleeding 
risks.26 A patient was classified as a “switcher” if they were prescribed warfarin, rivaroxaban or 
apixaban within 3 months prior to index date. We also performed subcategory analyses to assess 
the effects of gastroprotective agents for upper GIB and non-upper GIB. Since a number of case 
reports revealed an early onset of dabigatran-associated GIB,27-30 we conducted an additional 
analysis to evaluate the protective effect of gastroprotective agents on early bleeding defined as 
occurring within 30 days since commencement of dabigatran. For this analysis, only the first 30 
days since dabigatran commencement were included. 
A two-sided p-value <0.05 was considered as statistically significant. Statistical Analysis System 
(SAS) v9.3 (SAS Institute Inc., Cary, North Carolina) was used for statistical analysis. 
 
12 
 
Sensitivity analysis 
Several additional analyses were conducted to test the robustness of the main results. Since oral 
anticoagulants could exacerbate bleeding from underlying lesions, patients with prior history of 
peptic ulcer/GIB may be at higher risk of GIB.6,22 Therefore, in the first sensitivity analysis, we 
stratified the patients by prior history of peptic ulcer/GIB to explore the effect of gastroprotective 
agents in different risk groups. Another analysis was conducted by inclusion of AF patients only, 
which is the most common indication for dabigatran. The third sensitivity analysis accounted for 
the dosage effect of dabigatran on GIB by including the average daily dose as a covariate in an 
additional analysis. Finally, additional analyses were performed by stratifying the users of 
gastroprotective agents into patients who were continuously prescribed gastroprotective agents 
(continuous users), defined as those with a recorded supply of medication for ≥80% of the days 
of follow-up; and those who were not continuous users (i.e. infrequent users). 
Results 
Data validation  
Among the 5,041 patients on dabigatran included in this study, 711 (14.1%) patients were from 
the HKW cluster (Supplementary Figure 1). Of these, we selected all patients who had a 
diagnosis of GIB (n=35), all patients who had prior history of peptic ulcer/GIB (n=78), and a 
random sample of 133 (20%) patients who had AF.  As negative controls, we selected a random 
sample of 66 (10%) patients who did not develop GIB, a random sample of 63 (10%) patients 
who did not have prior history of peptic ulcer/GIB, and all patients who did not have AF (n=32). 
There were 63 patients being selected for validation of two medical conditions, and 8 patients 
being selected for validation of three medical conditions due to the random nature of the sample 
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selection. The final validation sample consisted of 328 patients. The corresponding PPVs and 
NPVs were: GIB, PPV=100%, NPV=98%; prior history of peptic ulcer/GIB, PPV=90%, 
NPV=92%; AF, PPV=95%, NPV=91%.    
Patient characteristics 
In total, 5,206 patients received dabigatran during the study period. Of these, five patients had 
dabigatran prescription(s) within one year prior to index date and were excluded. Further, 160 
patients who were being prescribed other oral anticoagulants on the index date were removed. 
The final analysis included 5,041 patients. The most common indication for dabigatran was AF 
(88.3%). The mean age of the patients was 72.0±10.9 years and 47.8% were male. The mean 
follow-up was 215±255 days and the total follow-up was 2,973 patient-years. Baseline 
characteristics of the patients are presented in Table 1.  
Risk of gastrointestinal bleeding 
There were 124 patients (2.5%) who developed GIB during follow-up. All cases were 
hospitalized with a diagnosis of GIB. Of these, 93 (75%) patients were admitted to hospital with 
GIB, and the remaining 31 (25%) patients developed GIB during hospitalization. The median 
length of hospital stay was 3 days (interquartile range: 5 days). Of the 124 bleeding cases, 55 
(44.4%) patients underwent endoscopy, 11 (8.9%) patients received transfusion, and 7 (5.6%) 
patients received both endoscopy and transfusion. There was one patient who died in the 
bleeding episode due to aspiration pneumonia. The median time to GIB was 36.5 days 
(interquartile range: 135.5 days) after the first prescription of dabigatran. The overall incidence 
of GIB in this cohort was 4.2 per 100 patient-years.   
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Patients aged ≥75 years (IRR, 2.47; 95%CI, 1.66-3.68), with a history of peptic ulcer/GIB (IRR, 
2.31; 95%CI, 1.54-3.46), or with concomitant use of aspirin (IRR, 1.52; 95%CI, 1.03-2.24) were 
found to have higher risk of GIB (Table 2).  
The risk of GIB was however significantly reduced with the concomitant use of gastroprotective 
agents. After adjusting for baseline medical conditions and concurrent medications, a reduction 
of 48% in the risk of GIB was found in users of gastroprotective agent as compared with non-
users (IRR, 0.52; 95%CI, 0.35-0.77) (Table 2). Sub-analysis showed that both PPIs (IRR, 0.53; 
95%CI, 0.31-0.91) and H2RAs (IRR, 0.61; 95%CI, 0.40-0.94) significantly reduced the risk of 
GIB. A further risk reduction was found in patients utilizing both H2RAs and PPIs over time 
(IRR, 0.15; 95%CI, 0.06-0.39). Figure 2 presents the Kaplan-Meier curves of the proportions of 
patients who were free of GIB. Similar risk reduction was noted among users of gastroprotective 
agents as compared with non-users (HR, 0.57; 95%CI, 0.38-0.85).  
Further analysis showed that the use of gastroprotective agents significantly reduced the risk of 
GIB in patients who had prior history of peptic ulcers/GIB (IRR, 0.14; 95%CI, 0.06-0.30) but not 
in patients with no prior history (IRR, 0.80; 95%CI, 0.50-1.28; Table 3).  In the subcategory 
analyses of sources of GIB into upper GIB and non-upper GIB, gastroprotective agents were 
found to significantly reduce the risk of upper GIB (IRR, 0.29; 95%CI, 0.15-0.54) but not non-
upper GIB (IRR, 0.75; 95%CI, 0.45-1.27). 
The sensitivity analysis which included patients with AF only yielded similar results. The use of 
gastroprotective agents was associated with a reduced risk of GIB in AF patients (IRR, 0.58; 
95%CI, 0.39-0.87); (Table 3). Similarly, a lower risk of GIB was observed in both new OAC 
starters (IRR, 0.56; 95%CI, 0.35-0.89) and switchers from other OAC (IRR, 0.38; 95%CI, 0.18-
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0.82) receiving gastroprotective agents. Even after adjusting for different dosages of dabigatran, 
the effects of gastroprotective agents in preventing GIB remained significant (IRR, 0.53; 95%CI, 
0.36-0.80). In the analysis for early GIB that developed within 30 days of dabigatran use, the 
concurrent use of gastroprotective agents were associated with a significant reduction in the risk 
of bleeding (IRR, 0.39; 95%CI, 0.22-0.69).  
Among all users of gastroprotective agents, about 70% used the drugs continuously during 
follow-up (Table 4). A reduction of the risk of GIB was observed among these patients as 
estimated by IRR (0.51; 95%CI, 0.34-0.77) and HR (0.57; 95%CI, 0.38-0.87). The effects of 
gastroprotective agents among the infrequent users were not statistically significant in general 
(Table 4). 
Discussion 
Gastrointestinal bleeding is a major adverse clinical outcome associated with the use of the 
NOACs. In particular, the bleeding risk appears to be higher for dabigatran when compared to 
other NOACs.6 As there is currently no effective antidote for dabigatran, patients are potentially 
at a higher risk of uncontrolled GIB as compared with warfarin, which can be reversed by 
vitamin K and fresh frozen plasma. This would highlight the importance of identifying a 
preventive strategy for GIB in patients taking dabigatran. This is the first population-based study 
that determines the role of gastroprotective agents on the risk of GIB among patients newly 
prescribed with dabigatran. We used the central electronic patient record database of the HA of 
Hong Kong which covers about 80% of all hospital admissions in Hong Kong.31 We found that 
the concomitant use of gastroprotective agents, including PPIs and H2RAs, significantly reduced 
the risk of GIB by 48% among patients on dabigatran. Of particular importance is that only 
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patients with a history of peptic ulcers or GIB, who were considered a high-risk group for GIB, 
were found to be significantly protected by gastroprotective agents. While NOAC could result in 
bleeding from small bowel or lower GI tract, our sub-analysis showed that the protective effect 
was statistically significant for upper GIB only. The results were also consistent for all 
sensitivity analyses, including testing on different indications and dosage effects of dabigatran 
and prior OAC experience.  
In this study, we found that old age (age≥75), a history of peptic ulcer/GIB and the concomitant 
use of aspirin were associated with higher risk of GIB among dabigatran users. This is consistent 
with previous observations that age and prior history of peptic ulcer/GIB are associated with 
higher risk of GIB among patients using NSAIDs or aspirin.32-34 Since many AF patients would 
have concurrent ischemic heart disease that would require aspirin, our data are supportive of 
further increase in risk of GIB when aspirin and dabigatran is co-administered. Particular caution 
is therefore mandatory in this group of patients who require both antiplatelet and anticoagulant 
therapies.  
Notably, we found that 67.5% of the dabigatran users in this cohort were concurrently prescribed 
gastroprotective agents. While a similar prescription rate was observed in the AF patients in Italy 
(65.3%)35, the prescription rate is higher than those reported in the RE-LY trial (17.6%)2 and 
other observation studies in the United States (24%)36 and Denmark (13.4%)37. A plausible 
explanation of the high prescribing rate is that clinicians may be more cautious about peptic ulcer 
disease and bleeding since gastrointestinal disorders is one of the most common diseases 
requiring hospital admission in Hong Kong.31 When compared to the West, Hong Kong has a 
higher prevalence of peptic ulcer disease.38-40  Therefore, it is possible that clinicians in Hong 
Kong have a higher tendency of prescribing gastroprotective agents compared to other countries. 
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Further, medications in HA are highly subsidized (85% to 98%) by the government.41 The low 
price of gastroprotection medications might also favor its use for various indications such as 
prophylaxis of ulcer and bleeding, maintenance therapy for gastroesophageal reflux diseases and 
non-cardiac chest pain among dabigatran users. 
The exact mechanism how gastroprotective agents prevent upper GIB in patients taking 
dabigatran remains unknown. Whilst the median time to bleeding after the use of dabigatran was 
approximately one month, the co-administration of PPI or H2RA may reduce the risk of bleeding 
from pre-existing gastroduodenal ulcers or erosions. Hence, the risk reduction was significantly 
higher among patients with prior history of peptic ulcer disease/GIB. Another possible 
explanation for the observed protective effect of gastroprotective agents may be mediated 
through acid suppression that interferes with absorption of dabigatran.  The formulation of 
dabigatran etexilate contains a tartaric acid core to provide an acidic environment required for 
drug absorption.1,2 It is biologically plausible that the acid suppressive effects of PPIs and 
H2RAs reduce the absorption of dabigatran. In the RE-LY trial, PPIs were observed to lower 
dabigatran exposures by 15%, but did not significantly reduce the overall clinical efficacy.42 
Further study is warranted to assess the potential risk-benefits of gastroprotection in patients on 
dabigatran by quantifying the risk of thromboembolism versus the benefit of preventing GIB. 
Unlike previous randomized controlled studies that had restrictive patient’s selection criteria,2-4 
our results were based on real-life clinical practice, through inclusion of all patients who were 
prescribed dabigatran. We utilized electronic database resources, which have been recognized to 
provide powerful platforms to conduct large-scale, real-life drug safety and post-marketing 
surveillance studies.43-46 By using the largest inter-linked clinical database in Hong Kong, we 
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observed a higher risk of dabigatan-related GIB in the Southern Chinese population group (4.2 
per 100 person-year) compared to other non-Asians patient groups as reported in Denmark (1.2 
to 1.5 per 100 person-year)37 and in the United States (0.6 to 3.4 per 100 person-year).7,47 The 
higher bleeding risk observed in our study population could not be explained by the dose of 
dabigatran used, as most (73%) of our patients were using the lower dosage of 220mg/day. In the 
RE-LY trial, the bleeding risk of Asians was higher than that of non-Asians despite younger age 
and comparable blood pressure.48 Similarly findings were reported in a retrospective cohort study 
of 18,867 AF patients that Asians had a higher risk of intracranial hemorrhage compared with the 
Whites, Blacks, and Hispanics.49 A possible mechanistic explanation of this observation could be 
explained by the genetic differences in blood coagulation between Asians and non-Asians.48 In 
particular, the factor V-Leiden mutations, which favors the formation of blood clots, is extremely 
rare in Asian but more commonly found in other ethnicities.50,51 It remains to be determined 
whether there are considerable ethnic differences on the clearance of drugs or whether the 
Chinese population is more susceptible to bleeding.52,53 
Our study has limitations. Similar to other clinical healthcare databases, CDARS does not 
capture the use of over-the-counter medications such as NSAIDs, which could lead to 
underestimation of the effect of concurrent medications on bleeding risk. However, in Hong 
Kong, non-aspirin oral NSAIDs in general are not over-the-counter medications and require a 
doctor’s prescription.54 Furthermore, the HA is the only publicly-funded primary care in Hong 
Kong where services and medications are highly subsidized (85% to 98%) by the government.41 
As a result, it is common for patients with chronic illness requiring long-term medications, such 
as patients with AF on dabigatran, to attend outpatient clinics of HA for ongoing treatment care 
rather than obtaining full-cost medications from over-the-counters.41 Therefore, it is anticipated 
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that the impact of missing of over-the-counter prescriptions would be minimal. As inherent in the 
retrospective cohort study design based on large population databases, we cannot exclude the 
possibility of residual confounding factors. In particular, other risk factors for peptic ulcer and 
bleeding such as Helicobacter pylori status and smoking history were lacking in this database. 
To overcome this potential limitation, we have included other possible confounding factors in 
our Poisson regression and added different sensitivity analyses in this study. The protective 
effects of PPI or H2RA appeared to be very consistent even after adjustment with indications or 
dosages of dabigatran and concurrent medical illnesses. With further analysis, the protective 
effect of gastroprotective agents against GIB was found to be more prominent in patients with 
prior history of peptic ulcer/GIB. Different sensitivity analyses or sub-analyses supported the 
consistency of the protective effects of gastroprotective agents.  
Our study also did not include control groups or comparator arms including conventional oral 
anticoagulants such as warfarin. However, several published epidemiological studies and clinical 
trials have compared dabigatran with traditional therapies, which consistently infer that 
dabigatran has a comparable or higher risk of GIB when compared to warfarin.2-4,7,37,55-57 Hence, 
our focus was to characterize the risks and protective factors of GIB associated with dabigatran, 
particularly in the Chinese population, where similar data are currently lacking. In addition, we 
could only access the medical records in CMS in a single hospital cluster for data validation, but 
not in all the seven clusters due to the limited access right. Therefore, potential bias could arise 
from any systematic differences in coding validity across different clusters. Nevertheless, CMS 
and CDARS are clinical health record databases. The information stored in CMS and CDARS 
are used for daily clinical management rather than insurance and reimbursement. Hence, the 
coding is not linked with any financial rewards or incentives, and the coding practice is most 
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likely to be non-differential between individual patients and hospital clusters, which are under 
the same management structure of the HA. As in our validation sample, the bleeding rate (35/711 
= 4.9%) appeared to be higher compared to the overall rate (2.5%). Since the HKW cluster is a 
tertiary referral center which tends to have referrals from cross-cluster patients with complex 
medical problems, the inclusion of these patients may have higher risk of bleeding than other 
patients.24 Finally, with a relatively smaller number of infrequent users of gastroprotective agents 
in this cohort, we cannot exclude the possibility that the non-significant results for the infrequent 
users were due to insufficient power. Further study is needed to confirm the results. 
Conclusions 
This study showed that the risk factors of GIB in our patients prescribed with dabigatran 
included age ≥75, history of peptic ulcer or GIB, and concomitant use of aspirin. 
Gastroprotective agents were associated with a reduced risk of GIB in patients on dabigatran. 
The protective effect seemed to be more on prevention of upper GIB and among those with a 
prior history of peptic ulcers or GIB. Hence, gastroprotective agents shall be considered in high-
risk patients taking dabigatran. Further prospective randomized clinical trial is warranted to 
confirm the effect of gastroprotective agents on reducing the risk of GIB in patients using 
dabigatran.  
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Figure 1. Study design 
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Figure 2. Kaplan-Meier curves of gastrointestinal bleeding. CI, confidence interval.  
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Table 1. Baseline characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics  n (%) 
Total 5041 
Age, mean ± standard deviation 72.0 ± 10.9 
Age ≥75 2368 (47.0) 
Sex (Male) 2412 (47.8) 
Baseline medical conditions   
    Congestive heart failure 893 (17.7) 
    Hypertension 2377 (47.2) 
    Diabetes mellitus 1079 (21.4) 
    Prior ischemic stroke/TIA/SE 1413 (28.0) 
    Renal disease 257 (5.1) 
    History of myocardial infarction 209 (4.1) 
    History of intracranial bleeding 121 (2.4) 
    History of peptic ulcer/GIB 700 (13.9) 
Concurrent medications   
    Aspirin 1538 (30.5) 
    Clopidogrel 211 (4.2) 
    Gastroprotective agentsa 3401 (67.5) 
    NSAIDs 523 (10.4) 
    SSRIs 210 (4.2) 
Indication for dabigatran  
    Atrial fibrillation 4451 (88.3) 
     Prophylaxis of VTE 572 (11.3) 
    Non-specified 18 (0.4) 
Dosage of dabigatran (average daily dose)  
    < 220mg 502 (10.0) 
       220mg 3686 (73.1) 
    > 220mg 730 (14.5) 
     Non-specified 123 (2.4) 
Abbreviations: TIA, transient ischemic attack; SE, systemic embolism; GIB, 
gastrointestinal bleeding; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective 
serotonin reuptake inhibitors; VTE, venous thromboembolism. 
a include proton pump inhibitors and histamine type-2 receptor antagonists 
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Table 2. Results of the main analysis 
 
 
 
 
 
 
 
n (%) Incidence rate ratios (95% CI) 
Total no. of patients 5041 - 
Total no. of patient years 2973 - 
No. of GIB 124 (2.5) - 
Age ≥75 2368 (47.0)   2.47 (1.66, 3.68)* 
Sex (Male) 2412 (47.8) 0.80 (0.55, 1.14) 
Baseline conditions   
    Prior ischemic stroke/TIA/SE 1413 (28.0) 1.31 (0.91, 1.89) 
    Renal disease 257 (5.1) 0.63 (0.26, 1.56) 
    History of peptic ulcer/GIB 700 (13.9)   2.31 (1.54, 3.46)* 
Concurrent Medication   
    Aspirin 1538 (30.5)   1.52 (1.03, 2.24)* 
    Clopidogrel 211 (4.2) 0.37 (0.09, 1.51) 
    Gastroprotective agents 3401 (67.5)   0.52 (0.35, 0.77)* 
       Histamine type-2 receptor antagonists 2004 (39.8)            0.61 (0.40, 0.94)* 
       Proton pump inhibitors 923 (18.3)   0.53 (0.31, 0.91)* 
       Both 474 (9.4)   0.15 (0.06, 0.39)* 
    NSAIDs 523 (10.4) 0.51 (0.22, 1.17) 
    SSRIs 210 (4.2) 0.51 (0.19, 1.40) 
Abbreviations:  GIB, gastrointestinal bleeding; TIA, transient ischemic attack; SE, systemic embolism; 
NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors;  
*p<0.05. 
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Table 3. Sensitivity analyses of the effect of gastroprotective agents on gastrointestinal bleeding 
 
 
N No. of GIB (%) Incidence rate ratio (95% CI) p-valuea 
Main model 5041 124 (2.5) 0.52 (0.35, 0.77)  
Stratified by prior OAC experienceb     
    New OAC starters 3967 91 (2.3) 0.56 (0.35, 0.89) 0.40 
    Switchers 1074 33 (3.1) 0.38 (0.18, 0.82)  
Subcategory analyses of the source of GIB     
    Upper GIB 5041 46 (0.9) 0.29 (0.15, 0.54) 0.02 
    Non-upper GIB 5041 78 (1.5) 0.75 (0.45, 1.27)  
Stratified by history of peptic ulcer/GIB     
    With history peptic ulcer/GIB 700 34 (4.9) 0.14 (0.06, 0.30) <0.001 
    No history of peptic ulcer/GIB 4341 90 (2.1) 0.80 (0.50, 1.28)  
Restricted to patients with atrial fibrillation only 4451 119 (2.7) 0.58 (0.39, 0.87)  
Adjusted for dosage effect of dabigatran   4918c 120 (2.4) 0.53 (0.36, 0.80)  
Early bleeding of dabigatrand 5041 56 (1.1) 0.39 (0.22, 0.69)  
Abbreviations: GIB, gastrointestinal bleeding; OAC, oral anticoagulant. 
a t-test was used to test for any differences in effect estimates within sub-groups. 
b Patients were classified as switchers if they were prescribed warfarin, rivaroxaban, or apixaban within 3 months prior to index date. 
Otherwise they were classified as new OAC starters. 
c 123 (2%) patients were excluded in the analysis due to unspecified dosage. 
d GIB that occurred within 30 days since commencement of dabigatran. 
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Table 4. Stratification into different use of gastroprotective agents 
 
Overalla H2RA alone PPI alone 
Both H2RA and 
PPIb 
All users, n (%) 3,401 2,004 923 474 
      Continuous usersc, n (%) 2,423 (71.2) 1,393 (69.5) 660 (71.5) 370 (78.1) 
      Infrequent usersc, n (%) 978 (28.8) 611 (30.5) 263 (28.5) 104 (21.9) 
Main model, incidence rate ratios (95% CI)     
      All users 0.52 (0.35, 0.77) 0.61 (0.40, 0.94) 0.53 (0.31, 0.91) 0.15 (0.06, 0.39) 
      Continuous usersc 0.51 (0.34, 0.77) 0.62 (0.40, 0.97) 0.48 (0.26, 0.87) 0.18 (0.07, 0.47) 
      Infrequent usersc 0.54 (0.31, 0.96) 0.59 (0.30, 1.15) 0.76 (0.32, 1.79) -d  
Time-to-event analysis, hazard rate ratios (95% CI)     
      All users 0.57 (0.38, 0.85) 0.66 (0.43, 1.01) 0.57 (0.34, 0.97) 0.19 (0.07, 0.49) 
      Continuous usersc 0.57 (0.38, 0.87) 0.68 (0.43, 1.06) 0.53 (0.29, 0.95) 0.23 (0.09, 0.60) 
      Infrequent usersc 0.57 (0.32, 1.00) 0.61 (0.31, 1.19) 0.74 (0.32, 1.75) -d 
Abbreviations: H2RA, histamine type-2 receptor antagonists; PPI, proton pump inhibitors; CI, confidence interval. 
a Includes H2RA and/or PPI. 
b Includes H2RA and PPI, either prescribed simultaneously or sequentially.  
c Patients who had day supply of drugs with ≥80% of the days of follow-up were classified as continuous users; otherwise they were 
classified as infrequent users. 
d No patients in this group developed gastrointestinal bleeding. 
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Supplementary Table 1. International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9) diagnosis codes used in this study 
ICD-9 codes Descriptions 
Gastrointestinal bleeding (GIB) 
Upper GIB 
531.0 Acute gastric ulcer with hemorrhage 
531.2 Acute gastric ulcer with hemorrhage and perforation, without mention of obstruction 
531.4 Chronic or unspecified gastric ulcer with hemorrhage 
531.6 Chronic or unspecified gastric ulcer with hemorrhage and perforation 
532.0 Acute duodenal ulcer with hemorrhage 
532.2 Acute duodenal ulcer with hemorrhage and perforation 
532.4 Chronic or unspecified duodenal ulcer with hemorrhage 
532.6 Chronic or unspecified duodenal ulcer with hemorrhage and perforation 
533.0 Acute peptic ulcer of unspecified site with hemorrhage 
533.2 Acute peptic ulcer of unspecified site with hemorrhage and perforation 
533.4 Chronic or unspecified peptic ulcer of unspecified site with hemorrhage 
533.6 
Chronic or unspecified peptic ulcer of unspecified site with hemorrhage and 
perforation 
534.0 Acute gastrojejunal ulcer with hemorrhage 
534.2 
Acute gastrojejunal ulcer with hemorrhage and perforation, without mention of 
obstruction 
534.4 Chronic or unspecified gastrojejunal ulcer with hemorrhage 
534.6 Chronic or unspecified gastrojejunal ulcer with hemorrhage and perforation 
535.01 Acute gastritis, with hemorrhage 
535.11 Atrophic gastritis, with hemorrhage 
535.21 Gastric mucosal hypertrophy, with hemorrhage 
535.31 Alcoholic gastritis, with hemorrhage 
535.41 Other specified gastritis, with hemorrhage 
535.51 Unspecified gastritis and gastroduodenitis, with hemorrhage 
535.61 Duodenitis, with hemorrhage 
535.71 Eosinophilic gastritis, with hemorrhage  
578.0 Hematemesis 
578.1 Melena 
578.9* Hemorrhage of gastrointestinal tract, unspecified 
  
Other GIB 
562.02 Diverticulosis of small intestine with hemorrhage 
562.03 Diverticulitis of small intestine with haemorrhage 
562.12 Diverticulosis of colon with haemorrhage 
562.13 Diverticulitis of colon with haemorrhage 
569.3 Hemorrhage of rectum and anus 
569.85 Angiodysplasia of intestine with haemorrhage 
569.86 Dieulafoy lesion (hemorrhagic) of intestine 
  
*578.9 was classified as upper GIB unless otherwise specified (e.g. in free-text). 
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Supplementary Table 1. International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9) diagnosis codes used in this study (continued). 
ICD-9 codes Descriptions 
Congestive Heart Failure 
398.91 Rheumatic heart failure (congestive)  
402.01 Malignant hypertensive heart disease with heart failure 
402.11 Benign hypertensive heart disease with heart failure 
402.91 Unspecified hypertensive heart disease with heart failure 
404.01 
Hypertensive heart and chronic kidney disease, malignant, with heart failure and 
with chronic kidney disease stage I through stage IV, or unspecified 
404.03 
Hypertensive heart and chronic kidney disease, malignant, with heart failure and 
with chronic kidney disease stage V or end stage renal disease 
404.11 
Hypertensive heart and chronic kidney disease, benign, with heart failure and with 
chronic kidney disease stage I through stage IV, or unspecified 
404.13 
Hypertensive heart and chronic kidney disease, benign, with heart failure and 
chronic kidney disease stage V or end stage renal disease  
404.91 
Hypertensive heart and chronic kidney disease, unspecified, with heart failure and 
with chronic kidney disease stage I through stage IV, or unspecified  
404.93 
Hypertensive heart and chronic kidney disease, unspecified, with heart failure and 
chronic kidney disease stage V or end stage renal disease 
428 Heart failure 
  
Hypertension  
401 Essential hypertension 
402 Hypertensive heart disease  
403 Hypertensive chronic kidney disease  
404 Hypertensive heart and chronic kidney disease  
405 Secondary hypertension 
437.2 Hypertensive encephalopathy 
  
Diabetes   
250 Diabetes mellitus 
  
Ischemic stroke/transient ischemic attack/systemic embolism 
433.01 Occlusion and stenosis of basilar artery with cerebral infarction   
433.11 Occlusion and stenosis of carotid artery with cerebral infarction   
433.21 Occlusion and stenosis of vertebral artery with cerebral infarction   
433.31 
Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral 
infarction   
433.81 Occlusion and stenosis of other specified precerebral artery with cerebral infarction  
433.91 Occlusion and stenosis of unspecified precerebral artery with cerebral infarction   
434 Occlusion of cerebral arteries   
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Supplementary Table 1. International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9) diagnosis codes used in this study (continued). 
ICD-9 codes Descriptions 
Ischemic stroke/transient ischemic attack/systemic embolism (continued) 
435 Transient cerebral ischemia   
436 Acute, but ill-defined, cerebrovascular disease 
437.0 Cerebral atherosclerosis   
437.1 Other generalized ischemic cerebrovascular disease   
444 Arterial embolism and thrombosis 
445 Atheroembolism 
  
Renal disease  
403 Hypertensive chronic kidney disease 
404 Hypertensive heart and chronic kidney disease 
580 Acute glomerulonephritis 
581 Nephrotic syndrome 
582 Chronic glomerulonephritis 
583 Nephritis and nephropathy not specified as acute or chronic 
584 Acute kidney failure 
585 Chronic kidney disease (ckd) 
586 Renal failure unspecified 
590.0 Chronic pyelonephritis 
753.1 Cystic kidney disease 
  
Myocardial infarction 
410 Acute myocardial infarction 
  
Intracranial hemorrhage 
430 Subarachnoid hemorrhage 
431 Intracerebral hemorrhage 
432 Other and unspecified intracranial hemorrhage 
  
Peptic ulcer/ Gastrointestinal bleeding 
531 Gastric ulcer 
532 Duodenal ulcer 
533 Peptic ulcer, site unspecified 
534 Gastrojejunal ulcer 
535 Gastritis and duodenitis  
578 Gastrointestinal hemorrhage 
  
Atrial fibrillation  
427.3 Atrial fibrillation and flutter 
